Advertisement

Alterations of Drug Transport

  • G. J. Goldenberg
  • A. Begleiter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 72)

Abstract

Twenty years ago, defective transport of the antimetabolite methotrexate was recognized as a specific cause of resistance to that drug in a mutant line of murine L5178Y leukemia (Fischer 1962). Since that time numerous reports of antitumor drug resistance based on defective drug transport have appeared involving several different groups of antitumor agents. In order to achieve a more complete understanding of this type of drug resistance, the basic mechanisms of drug uptake by mammalian cells will first be reviewed followed by a more detailed description of specific examples of drug resistance due to deficient transport. Next we will consider attempts that have been made to circumvent this type of resistance by increasing drug uptake in resistant transport mutants. The review will conclude with a brief discussion of the possible direction of future studies of this area of investigation.

Keywords

Resistant Cell Drug Transport Vinca Alkaloid Nitrogen Mustard Ehrlich Ascites Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmed K, Scholefleld PG (1962) Biochemical studies on 1-aminocyclopentane carboxylic acid. Can J Biochem Physiol 40:1101–1110PubMedCrossRefGoogle Scholar
  2. Akiyama S, Hidaka K, Komiyama S, Kuwano M (1979) Control of permeation of bleomycin A2 by polyene antibiotics in cultured Chinese hamster cells. Cancer Res 39:5150–5154PubMedGoogle Scholar
  3. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD (1968) Melphalan therapy for plasma cell myeloma. Blood 31:1–10PubMedGoogle Scholar
  4. Ardalan B, Cooney DA, Jayaram HM, Carrico CK, Glazer RI, MacDonald J, Schein PS (1980) Mechanism of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431–1437PubMedGoogle Scholar
  5. Balis ME, Hylin V, Coultas MK, Hutchison DJ (1958) Metabolism of resistant mutants of Streptococcus faecalis. II. Incorporation of exogenous purines. Cancer Res 18:220–225PubMedGoogle Scholar
  6. Ball CR, Connors TA, Double JA, Ujhazy V, Whisson ME (1966) Comparison of nitrogen mustard-sensitive and -resistant Yoshida sarcoma. Int J Cancer 1:319–327CrossRefGoogle Scholar
  7. Baskin F, Rosenberg RN (1975) Decreased 6-mercaptopurine retention by two resistant variants of mouse neuroblastoma with normal hypoxanthine-guanine-phosphoribosyl-transferase activity. J Pharmacol Exp Ther 193:293–300PubMedGoogle Scholar
  8. Baxter JD, Harris AW, Tomkins GM, Cohn M (1971) Glucocorticoid receptors in lymphoma cells in culture: relationship to glucocorticoid killing activity. Science 171:189–191PubMedCrossRefGoogle Scholar
  9. Bech-Hansen NT, Till JE, Ling V (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol 88:23–32PubMedCrossRefGoogle Scholar
  10. Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemia lymphoblasts. Cancer Res 39:2070–2076PubMedGoogle Scholar
  11. Begleiter A, Lam HYP, Goldenberg GJ (1977) Mechanism of uptake of nitrosoureas by L5178Y lymphoblasts in vitro. Cancer Res 37:1022–1027PubMedGoogle Scholar
  12. Begleiter A, Lam HYP, Grover J, Froese E, Goldenberg GJ (1979) Evidence for active transport of melphalan by amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 39:353–359PubMedGoogle Scholar
  13. Begleiter A, Grover J, Goldenberg GJ (1980) Uptake and metabolism of hexamethylmelamine and pentamethylmelamine by L5178Y lymphoblasts in vitro. Cancer Res 40:4489–4494PubMedGoogle Scholar
  14. Behrens UJ, Hollander VP (1976) Cell membrane sialoglycopeptides of corticoid-sensitive and -resistant lymphosarcoma P1798. Cancer Res 36:172–180PubMedGoogle Scholar
  15. Behrens UJ, Mashburn LT, Stevens J, Hollander VP, Lampen N (1974) Differences in cell surface characteristics between glucocorticoid-sensitive and -resistant mouse lymphomas. Cancer Res 34:2926–2932PubMedGoogle Scholar
  16. Bellamy D, Phillips JG, Jones IC, Leonard RA (1962) The uptake of Cortisol in rat tissues. Biochem J 85:537–545PubMedGoogle Scholar
  17. Bender RA, Nichols AP (1978) Membrane transport of vincristine (VCR) in human lym-phoblasts. Proc Am Assoc Cancer Res 19:35Google Scholar
  18. Bender RA, Bleyer WA, Frisby SA, Oliverio VT (1975) Alteration of methotrexate uptake in human leukemia cells by other agents. Cancer Res 35:1305–1308PubMedGoogle Scholar
  19. Bender RA, Nichols AP, Norton L, Simon RM (1978) Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vitro. Cancer Treat Rep 62:997–1003PubMedGoogle Scholar
  20. Bergel F, Stock JA (1953) Cytotoxic alpha amino acids and peptides. Br Emp Cancer Campaign Annu Rep 31:6–7Google Scholar
  21. Bergel F, Stock JA (1954) Cytoactive amino acids and derivatives. I. Substituted phenylalanines. J Chem Soc 2409–2417Google Scholar
  22. Bergsagel DE, Griffith KM, Haut A, Stuckey WJ Jr (1967) The treatment of plasma cell myeloma. Adv Cancer Res 10:311–359PubMedCrossRefGoogle Scholar
  23. Berlin RD, Oliver JM (1975) Membrane transport of purine and pyrimidine bases and nucleosides in animal cells. Int Rev Cytol 42:287–336PubMedCrossRefGoogle Scholar
  24. Bertino JR (1980) Approaches to drug selectivity in cancer therapy on the basis of differences between membranes of normal vs. neoplastic cells. Adv Pathobiol 7:377–386PubMedGoogle Scholar
  25. Bieber AL, Sartorelli AC (1964) The metabolism of thioguanine in purine analog-resistant cells. Cancer Res 24:1210–1215PubMedGoogle Scholar
  26. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin-D in Chinese hamster cells in vitro, in cross-resistance, radioautographic and cytogenetic studies. Cancer Res 30:1174–1184PubMedGoogle Scholar
  27. Bleyer WA, Frisby SA, Oliverio VT (1975) Uptake and binding of vincristine by murine leukemia cells. Biochem Pharmacol 24:633–639PubMedCrossRefGoogle Scholar
  28. Bonadonna G, Zucadi R, Monfardini S (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 36:252–259PubMedCrossRefGoogle Scholar
  29. Bo wen D, Goldman ID (1975) The relationship among transport, intracellular binding, and inhibition of RNA synthesis by actinomycin-D in Ehrlich ascites tumor cells in vitro. Cancer Res 35:3054–3060Google Scholar
  30. Breuer H, Rao ML, Rao GS (1974) Uptake of steroid hormones by isolated rat liver cells. J Steroid Biochem 5:359CrossRefGoogle Scholar
  31. Brink J J, LePage GA (1964) Metabolic effects of 9-D-arabinosylpurines in ascites tumor cells. Cancer Res 24:312–318PubMedGoogle Scholar
  32. Brockman RW (1961) Symposium on the experimental pharmacology and clinical use of antimetabolites. VI. Mechanisms of resistance to metabolite analogues with anticancer activity. Clin Pharmacol Ther 2:237–261Google Scholar
  33. Brockman RW (1963a) Mechanism of resistance to anticancer agents. Adv Cancer Res 7:129–234PubMedCrossRefGoogle Scholar
  34. Brockman RW (1963b) Biochemical aspects of mercaptopurine inhibition and resistance. Cancer Res 23:1191–1201PubMedGoogle Scholar
  35. Brockman RW (1965) Resistance to purine antagonists in experimental leukemia systems. Cancer Res 25:1596–1605PubMedGoogle Scholar
  36. Brockman RW, Debavadi CS, Stutts P, Hutchison DJ (1961) Purine ribonucleotide pyrophosphorylases and resistance to purine analogues inStreptococcus faecalis. J Biol Chem 236:1471–1479Google Scholar
  37. Brodsky I (1973) The role of androgens and anabolic steroids in the treatment of cancer. Semin Drug Treat 3:15–25PubMedGoogle Scholar
  38. Calabresi P, Parks RE Jr (1980) Chemotherapy of neoplastic diseases. In: Gilman AG, Goddman LS, Gilman A (eds) The pharmacologic basis of therapeutics, 6th edn. MacMillan, New York, pp 1290–1297Google Scholar
  39. Cardinali G, Cardinali G, Enein MA (1963) Studies on the antimitotic activity of leurocris-tine (vincristine). Blood 21:102–110Google Scholar
  40. Carlsen SA, Till JE, Ling V (1976) Modulation of membrane drug permeability in Chinese hamster ovary cells. Biochim Biophys Acta 455:900–912PubMedCrossRefGoogle Scholar
  41. Carlsen SA, Till JE, Ling V (1977) Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins. Biochim Biophys Acta 467:238–250PubMedCrossRefGoogle Scholar
  42. Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1:131–141PubMedGoogle Scholar
  43. Cass CE (1979) 9-β-D-Arabinofuranosyladenine. In: Hahn FE (ed) Antibiotics, mechanism of action, vol 5. Springer, Berlin Heidelberg New YorkGoogle Scholar
  44. Cass CE, Paterson ARP (1973) Mediated transport of nucleosides by human erythrocytes. Specificity toward purine nucleosides as permeants. Biochim Biophys Acta 291:734–746PubMedCrossRefGoogle Scholar
  45. Cass CE, Paterson ARP (1975) Inhibition by nitrobenzylthioinosine of uptake of adenosine, 2’-deoxyadenosine and 9-β-D-arabinosyladenine by human and mouse erythrocytes. Biochem Pharmacol 24:1989–1993PubMedCrossRefGoogle Scholar
  46. Cass CE, Turner AR, Seiner M, Allalunis MJ, Tan TH (1981) Effect of lithium on the myelosuppressive and chemotherapeutic activities of vinblastine. Cancer Res 41:1000–1005PubMedGoogle Scholar
  47. Chello PL, Sirotnak FM, Douck DM (1979) Different effects of vincristine on methotrexate uptake by L1210 cells and mouse intestinal epithelia in vitro and in vivo. Cancer Res 39:2106–2112PubMedGoogle Scholar
  48. Chervinsky DS, Wang JJ (1976) Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study. J Med 7:63–79PubMedGoogle Scholar
  49. Christensen HN (1966) Methods for distinguishing amino acid transport systems of a given cell or tissue. Fed Proc 25:850–853PubMedGoogle Scholar
  50. Christensen HN (1969) Some special kinetic problems of transport. Adv Enzymol 32:1–20PubMedGoogle Scholar
  51. Christensen HN, Handlogten ME (1968) Modes of mediated exodus of amino acids from the Ehrlich ascites tumor cell. J Biol Chem 243:5428–5438PubMedGoogle Scholar
  52. Christensen HN, Liang M (1965) An amino acid transport system of unassigned function in the Ehrlich ascites tumor cell. J Biol Chem 240:3601–3608PubMedGoogle Scholar
  53. Christensen HN, Liang M (1966) Modes of uptake of benzylamine by the Ehrlich cell. J Biol Chem 241:5552–5556PubMedGoogle Scholar
  54. Christensen HN, Liang M, Archer EG (1967) A distinct Na+-requiring transport system for alanine, serine, cysteine, and similar amino acids. J Biol Chem 242:5237–5246PubMedGoogle Scholar
  55. Chu MY, Fischer GA (1965) Comparative studies of leukemia cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14:333–341PubMedCrossRefGoogle Scholar
  56. Chu MY, Fischer GA (1968) The incorporation of 3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17:753–767PubMedCrossRefGoogle Scholar
  57. Chu BC, Whiteley JM (1980) The interaction of carrier-bound methotrexate with L1210 cells. Mol Pharmacol 17:382–387PubMedGoogle Scholar
  58. Chu BCF, Fan CC, Howell SB (1981) Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing metho-trexate-resistant LI210 cells. J Natl Cancer Inst 66:121–124PubMedGoogle Scholar
  59. Chun EHL, Gonzales L, Lewis FS, Jones J, Rutman RJ (1969) Differences in the in vivo alkylation and cross-linking of nitrogen mustard-sensitive and -resistant lines of Lettre-Ehrlich ascites tumors. Cancer Res 29:1184–1194PubMedGoogle Scholar
  60. Connors TA, Grover PL, McLoughlin AM (1970) Microsomal activation of cyclophosphamide in vivo. Biochem Pharmacol 19:1533–1535PubMedCrossRefGoogle Scholar
  61. Creasey WA (1968) Modifications in biochemical pathways produced by the vinca alkaloids. Cancer Chemother Rep 52:501–507PubMedGoogle Scholar
  62. Creasey WA, Markiw ME (1968) Uptake of vinblastine (VLB) by Ehrlich ascites carcinoma cells in vitro. Fed Proc 25:733Google Scholar
  63. Crichley V, Mager D, Bernstein A (1980) Colchicine resistant Friend cells: application to the study of actinomycin D induced erythroid differentiation. J Cell Physiol 102:63–70PubMedCrossRefGoogle Scholar
  64. Crooke ST, Bradner WT (1976) Mitomycin-C: a review. Cancer Treat Rev 3:121–139PubMedCrossRefGoogle Scholar
  65. Crowley ZG, Duwe SA (1969) Current status of the management of patients with endocrine-sensitive tumors. Calif Med 110:139–150PubMedGoogle Scholar
  66. Csuka O, Sugar J, Palyi I, Somfai-Relle S (1980) The mode of action of Vinca alkaloids. Oncology 37:83–87PubMedCrossRefGoogle Scholar
  67. Dano K (1972) Cross-resistance between Vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother Rep 56:701–708PubMedGoogle Scholar
  68. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483PubMedCrossRefGoogle Scholar
  69. Dano K, Frederiksen S, Hellung-Larsen P (1972) Inhibition of DNA and RNA synthesis by daunorubicin in sensitive and resistant Ehrlich ascites tumor cells in vitro. Cancer Res 32:1307–1314PubMedGoogle Scholar
  70. Dantzig AH, Slayman CW, Adelberg EA (1981) An amino acid transport mutant of Chinese hamster ovary cells resistant to the chemotherapeutic agent melphalan. Fed Proc 40:1894Google Scholar
  71. Davidson JD (1958) Permeability of resistant L1210 leukemia cells to 8-azaguanine and 6-mercaptopurine. Proc Am Assoc Cancer Res 2:290–291Google Scholar
  72. Davidson JD (1960) Studies on the mechanism of action of 6-marcaptopurine in sensitive and resistant L1210 leukemia in vitro. Cancer Res 20:225–232PubMedGoogle Scholar
  73. Debusscher L, Stryckmans PA (1978) Non-lymphocytic leukemia. In: Staquet MJ (ed) Randomized trials in cancer: a critical review by sites. Raven, New York, pp 25–54Google Scholar
  74. Dembo M, Sirotnak FM (1976) Antifolate transport in LI210 leukemia cells. Kinetic evidence for the non-identity of carriers for influx and efflux. Biochim Biophys Acta 448:505–516PubMedCrossRefGoogle Scholar
  75. Diamond I, Kennedy EP (1969) Carrier-mediated transport of choline into synaptic nerve endings. J Biol Chem 244:3258–3263PubMedGoogle Scholar
  76. Dicioccio RA, Srivastava BIS (1977) Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normal and leukemic human cells by 9-β-D-arabinofuranosyladenine 5′-triphosphate and l-β-D-arabinofuranosylcytosone 5′-triphosphate. Eur J Biochem 79:411–418PubMedCrossRefGoogle Scholar
  77. Di Marco A (1978) Mechanism of action and mechanism of resistance to antineoplastic agents that bind to DNA. Antibiot Chemother 23:216–227PubMedGoogle Scholar
  78. Easty GC, Stock J A, Ukleja-Bortkiewicz A (1972) Potentiation of the antitumor effect of rubidomycin by non-ionic detergents. Eur J Cancer 8:633–640PubMedCrossRefGoogle Scholar
  79. Eavenson E, Christensen HN (1967) Transport systems for neutral amino acids in the pigeon erythrocyte. J Biol Chem 242:5386–5396PubMedGoogle Scholar
  80. Einhorn LH, Donohue J (1977) ds-Diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298Google Scholar
  81. Elliott EM, Ling V (1981) Selection and characterization of Chinese hamster ovary cell mutants resistant to melphalan (L-phenylalanine mustard). Cancer Res 41:393–400PubMedGoogle Scholar
  82. Ezdinli EZ, Stutzman L, Aungst WC, Firat D (1969) Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 23:900–909PubMedCrossRefGoogle Scholar
  83. Fischer GA (1961) Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemia cells. Biochem Pharmacol 7:75–80PubMedCrossRefGoogle Scholar
  84. Fischer GA (1962) Defective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemia cells. Biochem Pharmacol 11:1233–1234PubMedCrossRefGoogle Scholar
  85. Flintoff W, Saya L (1978) The selection of wild-type revertants from methotrexate permeability mutants. Somatic Cell Gen 4:143–156CrossRefGoogle Scholar
  86. Foley GE, Friedman OM, Drolet BP (1961) Studies of the mechanism of action of Cytoxan. Evidence of activation in vivo and in vitro. Cancer Res 21:57–63PubMedGoogle Scholar
  87. Fry DW, Cybulski RL, Goldman ID (1980a) K+-induced alterations of energetics and exchange diffusion in the carrier-mediated transport of the folic acid analog, methotrexate, in Ehrlich ascites tumor cells. Biochim Biophys Acta 603:157–170PubMedCrossRefGoogle Scholar
  88. Fry DW, White JC, Goldman ID (1980b) Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional carrier fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells. Cancer Res 40:3669–3673PubMedGoogle Scholar
  89. Fujimoto J (1974) Radioautographic studies on the intracellular distribution of bleomycin-14C in mouse tumor cells. Cancer Res 34:2969–2974PubMedGoogle Scholar
  90. Furth J J, Cohen SS (1968) Inhibition of mammalian DNA polymerase by the 5′-triphosphate of l-β-D-arabinofuransylcytosine and the 5′-triphosphate of 9-β-d-arabinofuranosyladenine. Cancer Res 28:2061–2067PubMedGoogle Scholar
  91. Fyfe MJ, Goldman ID (1973) Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem 248:5067–5073PubMedGoogle Scholar
  92. Galivan J (1979) Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res 39:735–743PubMedGoogle Scholar
  93. Galivan J (1981) 5-Methyltetrahydrofolate transport by hepatoma cells and methotrexate-resistant sublines in culture. Cancer Res 41:1757–1762PubMedGoogle Scholar
  94. Garcia-Sancho J, Sanchez A, Christensen HN (1977) Role of proton dissociation in the transport of acidic amino acids by the Ehrlich ascites tumor cell. Biochim Biophys Acta 464:295–312PubMedCrossRefGoogle Scholar
  95. George P, Journey LJ, Goldstein MN (1965) Effects of vincristine on the fine structure of HeLa cells during mitosis. J Natl Cancer Inst 35:355–375PubMedGoogle Scholar
  96. Giorgi EP, Shirley IM, Grant JK, Stewart JC (1973) Androgen dynamics in vitro in the human prostate gland. Biochem J 132:465–474PubMedGoogle Scholar
  97. Giorgi EP, Moses TF, Grant JK, Scott R, Sinclair J (1974) In vitro studies of the regulation of androgen-tissue relationship in normal canine and hyperplastic human prostate. Mol Cell Endocrinol 1:271–284CrossRefGoogle Scholar
  98. Glover GI, D’Ambrosio SM, Jensen RA (1975) Versatile properties of a non-saturable homogeneous transport system in Bacillus subtilis: genetic, kinetic, and affinity labeling studies. Proc Natl Acad Sci USA 72:814–818PubMedCrossRefGoogle Scholar
  99. Goldenberg GJ (1969) Properties of L5178Y lymphoblasts highly resistant to nitrogen mustard. Ann NY Acad Sci 163:936–953CrossRefGoogle Scholar
  100. Goldenberg GJ (1975) The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L5178Y lymphoblasts. Cancer Res 35:1687–1692PubMedGoogle Scholar
  101. Goldenberg GJ, Begleiter A (1980) Membrane transport of alkylating agents. Pharmacol Ther 8:237–274PubMedCrossRefGoogle Scholar
  102. Goldenberg GJ, Vanstone CL, Israels LG, Ilse D, Bihler I (1970) Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts. Cancer Res 30:2285–2291PubMedGoogle Scholar
  103. Goldenberg GJ, Vanstone CL, Bihler I (1971a) Transport of nitrogen mustard on the transport carrier for choline in L5178 Y lymphoblasts. Science 172:1148–1149PubMedCrossRefGoogle Scholar
  104. Goldenberg GJ, Lyons RM, Lepp JA, Vanstone CL (1971b) Sensitivity to nitrogen mustard as a function of transport activity and proliferative rate in L5178Y lymphoblasts. Cancer Res 31:1616–1619Google Scholar
  105. Goldenberg GJ, Land HB, Cormack DV (1974) Mechanism of cyclophosphamide transport by L5178Y lymphoblasts in vitro. Cancer Res 34:3274–3282PubMedGoogle Scholar
  106. Goldenberg GJ, Lee M, Lam HYP, Begleiter A (1977) Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 37:755–760PubMedGoogle Scholar
  107. Goldenberg GJ, Lam HYP, Begleiter A (1978) Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. Clin Res 26:874AGoogle Scholar
  108. Goldenberg GJ, Lam HYP, Begleiter A (1979) Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chem 254:1057–1064PubMedGoogle Scholar
  109. Goldman ID (1969) Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. J Biol Chem 244:3779–3785PubMedGoogle Scholar
  110. Goldman ID (1971a) The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 186:400–422PubMedCrossRefGoogle Scholar
  111. Goldman ID (1971b) A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in LI210 leukemia and Ehrlich ascites tumor cells. Biochim Biophys Acta 233:624–634PubMedCrossRefGoogle Scholar
  112. Goldman ID, Lichtenstein NS, Oliverio VT (1968) Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 243:5007–5017PubMedGoogle Scholar
  113. Goldman ID, Gupta V, White JC, Loftfield S (1976) Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid “rescue” protocols. Cancer Res 36:276–279PubMedGoogle Scholar
  114. Goldstein MN, Slotnick I J, Journey LJ (1960) In vitro studies with Hela cell lines sensitive and resistant to actinomycin-D. Ann NY Acad Sci 89:474–483PubMedCrossRefGoogle Scholar
  115. Goldstein MN, Hamm K, Amrod E (1966) Incorporation of tritiated actinomycin-D into drug-sensitive and drug-resistant Hela cells. Science 151:1555–1556PubMedCrossRefGoogle Scholar
  116. Gotto AM, Belkhode ML, Touster O (1969) Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14C, 5-fluorouracil-2-14C, and 5-bromouracil-2-14C into nucleic acids by Ehrlich ascites tumor cells in vitro. Cancer Res 29:807–811PubMedGoogle Scholar
  117. Gout PW, Wijcik LL, Beer CT (1978) Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells. Eur J Cancer 14:1167–1178PubMedCrossRefGoogle Scholar
  118. Gross SR, Aronow L, Pratt WB (1968) The active transport of Cortisol by mouse fibroblasts growing in vitro. Biochem Biophys Res Commun 32:66–72PubMedCrossRefGoogle Scholar
  119. Gross SR, Aronow L, Pratt WB (1970) The outward transport of Cortisol by mammalian cells in vitro. J Cell Biol 44:103–114PubMedCrossRefGoogle Scholar
  120. Gustafsson JA, Ekman P, Snochowski M, Zetterberg A, Pousette A, Hogberg B (1978) Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer. Cancer Res 38:4345–4358PubMedGoogle Scholar
  121. Hakala MT (1965) On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochim Biophys Acta 102:210–225PubMedCrossRefGoogle Scholar
  122. Hall TC, Choi OS, Abadi A, Krant MJ (1967) High-dose corticoid therapy in Hodgkin’s disease and other lymphomas. Ann Intern Med 66:1144–1153PubMedGoogle Scholar
  123. Hanby WE, Hartley GS, Powell EO, Rydon HN (1947) The chemistry of 2-chloroalkylamines. Part II. Reactions of tertiary 2-chloroalkylamines in water. J Chem Soc 519–533Google Scholar
  124. Harrap KR, Hill BT (1969) The selectivity of action of akylating agents and drug resistance. 1. Biochemical changes occurring in sensitive and resistant strains of the Yoshida ascites sarcoma following chemotherapy. Br J Cancer 23:210–226PubMedCrossRefGoogle Scholar
  125. Harrap KR, Hill BT (1970) The selectivity of action of alkylating agents and drug resistance. 3. The uptake and degradation of alkylating drugs by Yoshida ascites sarcoma cells in vitro. Biochem Pharmacol 19:209–217PubMedCrossRefGoogle Scholar
  126. Harrap KR, Jackson RC (1978) Biochemical mechanisms of resistance to antimetabolites. Antibiot Chemother 23:228–237PubMedGoogle Scholar
  127. Hawkins RA, Berlin RD (1969) Purine transport in polymorphonuclear leukocytes. Biochim Biophys Acta 173:324–337PubMedCrossRefGoogle Scholar
  128. Hebden HF, Hadfield JR, Beer CT (1970) The binding of vinblastine by platelets in the rat. Cancer Res 30:1417–1424PubMedGoogle Scholar
  129. Heidelberger C (1965) Fluorinated pyrimidines. Prog Nucleic Acid Res Mol Biol 4:1–50PubMedCrossRefGoogle Scholar
  130. Heidelberger C, Kaldor G, Mukherjee KL, Danneberg PB (1960) Studies on fluorinated pyrimidines XI. In vitro studies on tumor resistance. Cancer Res 20:903–909PubMedGoogle Scholar
  131. Hilf R, Wittliff JL (1975) Mechanisms of action of estrogens. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents II. Springer, Berlin Heidelberg New YorkGoogle Scholar
  132. Hill BT (1972) Studies on the transport and cellular distribution of chlorambucil in the Yoshida ascites sarcoma. Biochem Pharmacol 21:495–502PubMedCrossRefGoogle Scholar
  133. Hill BT, Jarman M, Harrap KR (1971) Selectivity of action of alkylating agents and drug resistance. 4. Synthesis of tritium-labeled chlorambucil and a study of its cellular uptake by drug-sensitive and drug-resistant strains of the Yoshida ascites sarcoma in vitro. J Med Chem 14:614–618PubMedCrossRefGoogle Scholar
  134. Hill BT, Bailey BD, White JC, Goldman ID (1979) Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 39:2440–2446PubMedGoogle Scholar
  135. Hirnes RH, Kersey RN, Heller-Bettinger I, Samson FE (1976) Action of the Vinca alkaloids vincristine, vinblastine and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36:3798–3802Google Scholar
  136. Hirono I, Kachi H, Ohashi H (1962) Mechanism of natural and acquired resistance to methyl-bis(2-chloroethyl)amine N-oxide in ascites tumors. II. Permeability of tumor cells to alkylating agents. Gan 53:73–80PubMedGoogle Scholar
  137. Ho DHW, Frei E (1971) Clinical pharmacology of l-β-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954PubMedGoogle Scholar
  138. Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA, Townsend SR, Harley JB, Hayes DB, Costa G, Holland JF (1967) Melphalan and multiple myeloma. Blood 30:74–83PubMedGoogle Scholar
  139. Inaba M (1973) Mechanism of resistance of Yoshida sarcoma to nitrogen mustard. III. Mechanism of suppressed transport of nitrogen mustard. Int J Cancer 11:231–236PubMedCrossRefGoogle Scholar
  140. Inaba M, Johnson RK (1978) Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. Biochem Pharmacol 27:2123–2130PubMedCrossRefGoogle Scholar
  141. Inaba M, Sakurai Y (1979) Enhanced efflux of actinomycin-D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia. Cancer Lett 8:111–115PubMedCrossRefGoogle Scholar
  142. Inaba M, Kobayashi H, Sakurai Y, Johnson RK (1979) Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39:2200–2203PubMedGoogle Scholar
  143. Jacquez JA (1962) Permeability of Ehrlich cells to uracil, thymine, and fluorouracil. Proc Soc Exp Biol Med 109:132–135PubMedGoogle Scholar
  144. Jacquez JA (1975) One-way fluxes of a-amino-isobutyric acid in Ehrlich ascites tumor cells. J Gen Physiol 65:57–83PubMedCrossRefGoogle Scholar
  145. Journey LG, Burdman J, George P (1968) Ultrastructural studies on tissue culture cells treated with vincristine. Cancer Chemother Rep 52:509–517PubMedGoogle Scholar
  146. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162PubMedCrossRefGoogle Scholar
  147. Juliano R, Ling Y, Graves J (1976) Drug-resistant mutants of Chinese hamster ovary cells possess an altered cell surface carbohydrate component. J Supramol Struct 4:521–526PubMedCrossRefGoogle Scholar
  148. Kano K, Fendler JH (1977) Enhanced uptake of drugs in liposomes: use of labile vitamin B12 complexes of 6-mercaptopurine and 8-azaguanine. Life Sci 20:1729–1734PubMedCrossRefGoogle Scholar
  149. Kaplan L (1968) Cancer of the prostate: estrogen therapy. Natural conjugated estrogen vs. stilboestrol. Rev Surg 25:323–329PubMedGoogle Scholar
  150. Kasbekar DK, Greenberg DM (1963) Studies in tumor resistance to 5-fluorouracil. Cancer Res 23:818–824PubMedGoogle Scholar
  151. Kelley RM, Baker WH (1960) Clinical observations on the effect of progesterone in the treatment of metastatic endometrial carcinoma. In: Pincus G, Vollmer E (eds) Biological activities of steroids in relation to cancer. Academic, New York, pp 447–455Google Scholar
  152. Kelley RM, Baker WH (1970) Progestational agents in the treatment of carcinoma of the genitourinary tract. In: Sturgis S, Taymore M (eds) Progress in gynecology. Grune and Stratton, New York, pp 362–375Google Scholar
  153. Kennedy BJ (1968) Progestogens in the treatment of carcinoma of the endometrium. Surg Gynecol Obstet 127:103–114PubMedGoogle Scholar
  154. Kessel D (1971) Determinants of camptothecin responsiveness in leukemia L1210 cells. Cancer Res 31:1883–1887PubMedGoogle Scholar
  155. Kessel D, Bosmann HB (1970) On the characteristics of actinomycin D resistance in L5178Y cells. Cancer Res 30:2695–2701PubMedGoogle Scholar
  156. Kessel D, Hall TC (1967) Studies on drug transport by normal human leukocytes. Biochem Pharmacol 16:2395–2403PubMedCrossRefGoogle Scholar
  157. Kessel D, Hall TC (1969 a) Influence of ribose donors on the action of 5-fluorouracil. Cancer Res 29:1749–1754Google Scholar
  158. Kessel D, Hall TC (1969 b) Retention of 6-mercaptopurine derivatives by intact cells as an index of drug response in human and murine leukemias. Cancer Res 29:2116–2119Google Scholar
  159. Kessel D, Shurin SB (1968) Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside in a subline of L1210 murine leukemia. Biochim Biophys Acta 163:179–187PubMedCrossRefGoogle Scholar
  160. Kessel D, Wodinsky I (1968) Uptake in vivo and in vitro of actinomycin D by mouse leu-kemias as factors in survival. Biochem Pharmacol 17:161–164PubMedCrossRefGoogle Scholar
  161. Kessel D, Hall TC, Roberts D (1965) Uptake as a determinant of methotrexate response in mouse leukemias. Science 150:752–753PubMedCrossRefGoogle Scholar
  162. Kessel D, Hall TC, Wodinsky I (1966) Nucleotide formation as a determinant of 5-fluorouracil response in mouse leukemias. Science 154:911–913PubMedGoogle Scholar
  163. Kessel D, Hall TC, Roberts D (1968) Modes of uptake of methotrexate by normal and leukemic human leukocytes in vitro and their relation to drug response. Cancer Res 28:564–570PubMedGoogle Scholar
  164. Kessel D, Meyers M, Wodinsky I (1969) Accumulation of two alkylating agents, nitrogen mustard and busulfan, by murine leukemia cells in vitro. Biochem Pharmacol 18:1229–1234PubMedCrossRefGoogle Scholar
  165. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334PubMedCrossRefGoogle Scholar
  166. Klatt O, Stechlin JS Jr, McBride C, Griffin AC (1969) The effect of nitrogen mustard treatment on the deoxyribonucleic acid of sensitive and resistant Ehrlich tumor cells. Cancer Res 29:286–290PubMedGoogle Scholar
  167. Kneale B, Evans J (1969) Progestogen therapy for advanced carcinoma of the endometrium. Med J Aust 2:1101–1104PubMedGoogle Scholar
  168. Koren R, Shohami E, Yeroushalmi S (1979) A kinetic analysis of the uptake of cytosine-β-D-arabinoside by rat-B77 cells. Eur J Biochem 95:333–339PubMedCrossRefGoogle Scholar
  169. Koshiura R, LePage GA (1968) Some inhibitors of deamination of 9-β-D-arabinofuranosyladenine and 9-β-D-xylofuranosyladenine by blood of neoplasms of experimental animals and humans. Cancer Res 28:1014–1020Google Scholar
  170. Kotler-Brajtburg J, Medoff G, Kobayashi GS, Boggs S, Schlessinger D, Pandey RC, Rinehalt KL Jr (1979) Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agents Chemother 15:716–722PubMedGoogle Scholar
  171. Kung S, Goldberg ND, Dahl JL, Parks RE Jr (1963) Potentiation of 5-fluorouracil inhibition of Flexner-Jobling carcinoma by glucose. Science 141:627–628PubMedCrossRefGoogle Scholar
  172. Kupferberg HJ (1969) Inhibition of ouabain-H3 uptake by liver slices and its excretion into the bile by compounds having a steroid nucleus. Life Sci 8:1179–1185PubMedCrossRefGoogle Scholar
  173. Lam HYP, Begleiter A, Stein WD, Goldenberg GJ (1978) On the mechanism of uptake of procarbazine by L5178Y lymphoblasts in vitro. Biochem Pharmacol 27:1883–1885PubMedCrossRefGoogle Scholar
  174. Lam HYP, Talgoy MM, Goldenberg GJ (1980) Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro. Cancer Res 40:3950–3955PubMedGoogle Scholar
  175. Langelier Y, Simard R, Brailovsky C (1974) Mechanism of actinomycin resistance in SV40-transformed hamster cells. Differentiation 2:261–267PubMedCrossRefGoogle Scholar
  176. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT (1979) Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res 39:383–390PubMedGoogle Scholar
  177. Layton D, Trouet A (1980) A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leukemic mice. Eur J Cancer 16:945–950PubMedCrossRefGoogle Scholar
  178. Lee SH, Sartorelli AC (1981) Conversion of 6-thioguanine to the nucleoside level by purine nucleoside phosphorylase of sarcoma 180 and sarcome 180/TG ascites cells. Cancer Res 41:1086–1090PubMedGoogle Scholar
  179. Lee ML, Huang YM, Sartorelli AC (1978) Alkaline phosphatase activities of 6-thiopurine-sensitive and -resistant sublines of sarcoma 180. Cancer Res 38:2413–2418PubMedGoogle Scholar
  180. Leo A, Hansch C, Elkins D (1971) Partition coefficients and their uses. Chem Rev 71:525–616CrossRefGoogle Scholar
  181. LePage GA (1960) Incorporation of 6-thioguanine in nucleic acids. Cancer Res 20:403–408PubMedGoogle Scholar
  182. LePage GA, Jones M (1961) Further studies on the mechanism of action of 6-thioguanine. Cancer Res 21:1590–1594PubMedGoogle Scholar
  183. LePage GA, Junga IG, Bowman B (1964) Biochemical and carcinostatic effects of 2′-deoxythioguanosine. Cancer Res 24:835–840PubMedGoogle Scholar
  184. Lieb WR, Stein WD (1969) Biological membranes behave as non-porous polymeric sheets with respect to the diffusion of non-electrolytes. Nature 224:240–243PubMedCrossRefGoogle Scholar
  185. Lieb WR, Stein WD (1971) The molecular basis of simple diffusion within biological membranes. In: Koeinzeller A, Bronner FR (eds) Current topics in membranes and transport, vol 2. Academic, New York, pp 1–39Google Scholar
  186. Ling V (1975) Drug resistance and membrane alteration in mutants of mammalian cells. Can J Genet Cytol 17:503–515PubMedGoogle Scholar
  187. Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83:103–116PubMedCrossRefGoogle Scholar
  188. Lippman ME, Perry S, Thompson EB (1974) Cytoplasmic glucocorticoid-binding proteins in glucocorticoid-unresponsive human and mouse leukemic cell lines. Cancer Res 34:1572–1576PubMedGoogle Scholar
  189. Lippman ME, Yarbro GK, Leventhal BG (1978) Clinical implications of glucocorticoid receptors in human leukemia. Cancer Res 38:4251–4256PubMedGoogle Scholar
  190. Lyons RM, Goldenberg GJ (1972) Active transport of nitrogen mustard and choline by normal and leukemic human lymphoid cells. Cancer Res 32:1679–1685PubMedGoogle Scholar
  191. Malawista SE, Sato H, Bensch KG (1968) Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science 160:770–772PubMedCrossRefGoogle Scholar
  192. Mauer AM, Simone JV (1976) The current status of the treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rev 3:17–41PubMedCrossRefGoogle Scholar
  193. Meyers MB, Biedler JL (1981) Increased synthesis of a low-molecular-weight protein in vincristine-resistant cells. Biochem Biophys Res Commun 99:228–235PubMedCrossRefGoogle Scholar
  194. Milgrom E, Atger M, Baulieu EE (1973) Studies on estrogen entry into uterine cells and on estradiol-receptor complex attachment to the nucleus. Is the entry of estrogen into uterine cells a protein-mediated process? Biochim Biophys Acta 320:267–283PubMedCrossRefGoogle Scholar
  195. Miura Y, Moriyama A (1961) Studies on the metabolism of rat ascites tumor with nitrogen mustard sensitive and resistant strains. VI. Inhibition of the in vitro incorporation of C14-orotic acid into nucleic acids by nitrogen mustard. J Biochem (Tokyo) 50:362–366Google Scholar
  196. Miyaki M, Ono T, Hori S, Umezawa H (1975) Binding of bleomycin to DNA in bleomycin-sensitive and -resistant rat ascites hepatoma cells. Cancer Res 35:2015–2019PubMedGoogle Scholar
  197. Momparler RL, Chu MY, Fischer GA (1968) Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta 161:481–493PubMedGoogle Scholar
  198. Mulder JA, Harrap KR (1975) Cytosine arabinoside uptake by tumor cells in vitro. Eur J Cancer 11:373–379PubMedCrossRefGoogle Scholar
  199. Muller WEG, Rohde HJ, Beyer R, Maidhof A, Lachmann M, Taschner H, Zahn RK (1975) Mode of action of 9-β-D-arabinofuranosyladenine on the synthesis of DNA, RNA and protein in vivo and in vitro. Cancer Res 35:2160–2168PubMedGoogle Scholar
  200. Muller WEG, Maidhof A, Zahn RK, Shannon WM (1977) Effect of 9-β-D-arabinofurano-syladenine on DNA synthesis in vivo. Cancer Res 37:2282–2290PubMedGoogle Scholar
  201. Munck A, Wira C, Young DA, Mosher KM, Hallahan C, Bell PA (1972) Glucocorticoid-receptor complexes and the earliest steps in the actions of glucocorticoids on thymus cells. J Steroid Biochem 3:567–578PubMedCrossRefGoogle Scholar
  202. Nachman J, Baum E, Nortis D, Ramsay N, Weetman R, Neerhout R, Griffin T, Littman P, Sather H, Chard R, Hammond D (1981) Prolonged remission after bone marrow (BM) relapse in childhood acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol 22:476Google Scholar
  203. Neal JL (1972) Analysis of Michaelis kinetics for two independent saturable membrane transport functions. J Theor Biol 35:113–118PubMedCrossRefGoogle Scholar
  204. Nelson JA, Kuhns JN, Carpenter JW (1975) Lack of activity of β-2’-deoxythioguanosine against two tumors resistant to 6-thioguanine. Cancer Res 35:1372–1374PubMedGoogle Scholar
  205. Nichols WW (1964) In vitro chromosome breakage induced by arbinosyladenine in human leukocytes. Cancer Res 24:1502–1505PubMedGoogle Scholar
  206. Nicholson ML, Young DA (1978) Effect of glucocorticoid hormones in vitro on the structural integrity of nuclei in corticosteroid-sensitive and -resistant lines of lymphosarcoma P1798. Cancer Res 38:3673–3680PubMedGoogle Scholar
  207. Nicholson ML, Voris BP, Young DA (1981) Proteins associated with emergence of the resistance to lethal glucocorticoid actions in P1798 mouse lymphosarcoma cells. Cancer Res 41:3530–3537PubMedGoogle Scholar
  208. Niethammer D, Jackson RC (1975) Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11:845–854PubMedCrossRefGoogle Scholar
  209. Orstavik J (1974) Uptake and release of 3H-mitomycin-C in mouse P388 cell cultures. Acta Pathol Microbiol Scand [B] 82:270–276Google Scholar
  210. Owellen RJ, Owens AH Jr, Donigian DW (1972) The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Common 47:685–691CrossRefGoogle Scholar
  211. Owellen RJ, Donigian DW, Hartke CA, Dickerson RM, Kuhar MJ (1974) The binding of vinblastine to tubulin and to particulate fractions of mammalian brain. Cancer Res 34:3180–3186PubMedGoogle Scholar
  212. Owellen RJ, Hartke CA, Dickerson RM, Hains FO (1976) Inhibition of tubulin-microtu-bule polymerization of drugs of the Vinca alkaloid class. Cancer Res 36:1499–1502PubMedGoogle Scholar
  213. Oxender DL, Christensen HN (1963) Distinct mediating systems for the transport of neutral amino acids by the Ehrlich cell. J Biol Chem 238:3686–3699PubMedGoogle Scholar
  214. Oxender DL, Lee M, Moore PA, Cecchini G (1977) Neutral amino acid transport systems of tissue culture cells. J Biol Chem 252:2675–2679PubMedGoogle Scholar
  215. Pall ML (1970) Amino acid transport activity in Neurospora crassa. II. Properties of a basic amino acid transport system. Biochim Biophys Acta 203:139–140PubMedCrossRefGoogle Scholar
  216. Palmer CG, Livengood D, Warren AK, Simpson PJ, Johnson IS (1960) The action of vin-caleukoblastine on mitosis in vitro. Exp Cell Res 20:198–201PubMedCrossRefGoogle Scholar
  217. Parsons PG, Carter FB, Morrison L, SR Regius Mary (1981) Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 41:1525–1534PubMedGoogle Scholar
  218. Paterson ARP (1962) Resistance to 6-mercaptopurine. II. The synthesis of thioinosinate in a 6-mercaptopurine-resistant subline of the Ehrlich ascites carcinoma. Can J Biochem Physiol 40:195–206PubMedCrossRefGoogle Scholar
  219. Paterson ARP, Hori A (1962) Resistance to 6-mercaptopurine. I. Biochemical differences between the Ehrlich ascites carcinoma and a 6-mercaptopurine-resistant subline. Can J Biochem Physiol 40:181–194PubMedCrossRefGoogle Scholar
  220. Peck EJ Jr, Burgner J, Clark JH (1973) Estrophilic binding sites of the uterus. Relation to uptake and retention of estradiol in vitro. Biochemistry 12:4596–4603PubMedCrossRefGoogle Scholar
  221. Plagemann PGW, Marz R, Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and l-β-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation and regulation of triphosphate synthesis. Cancer Res 38:978–989PubMedGoogle Scholar
  222. Poste G, Papahadjopoulos D (1976) Drug-containing lipid vesicles render drug-resistant tumor cells sensitive to actinomycin-D. Nature 261:699–701PubMedCrossRefGoogle Scholar
  223. Potter LT (1968) Uptake of choline by nerve endings isolated from the rat cerebral cortex. In: Campbell PN (ed) Interaction of drugs and subcellular components. Churchill, London, pp 293–304Google Scholar
  224. Rader JF, Niethammer D, Huennekens FM (1974) Effects of sulphydryl inhibitors upon transport of folate compounds into LI 210 cells. Biochem Pharmacol 23:2057–2059PubMedCrossRefGoogle Scholar
  225. Rao ML, Rao GS, Holler M, Breuer H (1974) Uptake of Cortisol by isolated rat liver cells. Hoppe Seylers Z Physiol Chem 355:1239–1240PubMedCrossRefGoogle Scholar
  226. Rao GS, Schulze-Hagen K, Rao ML, Breuer H (1976a) Kinetics of steroid transport through cell membranes: comparison of the uptake of Cortisol by isolated rat liver cells with binding of Cortisol to rat liver cytosol. J Steroid Biochem 7:1123–1129PubMedCrossRefGoogle Scholar
  227. Rao ML, Rao GS, Holler M, Breuer H, Schattenberg PJ, Stein WD (1976b) Uptake of Cortisol by isolated rat liver cells. A phenomenon indicative of carrier-mediated and simple diffusion. Hoppe Seylers Z Physiol Chem 357:573–584PubMedCrossRefGoogle Scholar
  228. Rao ML, Rao GS, Breuer H (1977) Uptake of estrone, estradiol-17β and testosterone by isolated rat liver cells. Biochem Biophys Res Commun 77:566–573PubMedCrossRefGoogle Scholar
  229. Redwood WR, Colvin M (1980) Transport of melphalan by sensitive and resistant LI210 cells. Cancer Res 40:1144–1149PubMedGoogle Scholar
  230. Reichard P, Skold O, Klein G (1959) Possible enzymie mechanism for the development of resistance against fluorouracil in ascites tumors. Nature 183:939–941PubMedCrossRefGoogle Scholar
  231. Reichard P, Skold O, Klein G, Renesz L, Magnusson P (1962) Studies on resistance against 5-fluorouracil. I. Enzymes of the uracil pathway during development of resistance. Cancer Res 22:235–243PubMedGoogle Scholar
  232. Reiser S, Fitzgerald JF, Christensen PA (1970) Kinetics of the accelerated intestinal valine transport in 2-day-old rats. Biochim Biophys Acta 203:351–353PubMedCrossRefGoogle Scholar
  233. Riehm H, Biedler JL (1971) Cellular resistance to daunomycin in Chinese hamster cells in vitro. Cancer Res 31:409–412PubMedGoogle Scholar
  234. Riehm H, Biedler JL (1972) Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin-D and daunomycin. Cancer Res 32:1195–1200PubMedGoogle Scholar
  235. Rigberg SV, Brodsky I (1975) Potential roles of androgens and the anabolic steroids in the treatment of cancer — a review. J Med 6:271–290PubMedGoogle Scholar
  236. Riordan JR, Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254:12701–12705PubMedGoogle Scholar
  237. Rosowsky A, Lazarus H, Yuan GC, Beltz WR, Mangini L, Abelson HT, Modest EJ, Frei E (1980) Effects of methotrexate esters and other lipophilic antifolates on methotrex-ate-resistant human leukemic lymphoblasts. Biochem Pharmacol 29:648–652PubMedCrossRefGoogle Scholar
  238. Rutman RJ, Chun EHL, Lewis FS (1968) Permeability differences as a source of resistance to alkylating agents in Ehrlich tumor cells. Biochem Biophys Res Commun 32:650–657PubMedCrossRefGoogle Scholar
  239. Rysser HJP, Shen WC (1978) Conjugation of methotrexate to poly (L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 75:3867–3870CrossRefGoogle Scholar
  240. Rysser HJP, Shen WC (1980) Conjugation of methotrexate to poly (L-lysine) as a potential way to overcome drug resistance. Cancer 45:1207–1211CrossRefGoogle Scholar
  241. Salser JS, Hutchison DJ, Balis ME (1960) Studies on the mechanism of action of 6-mercap-topurine in cell-free preparations. J Biol Chem 235:429–432PubMedGoogle Scholar
  242. Sartorelli AC, LePage GA (1958) Metabolic effects of 6-thioguanine. II. Biosynthesis of nucleic acid purines in vivo and in vitro. Cancer Res 18:1329–1335PubMedGoogle Scholar
  243. Sartorelli AC, LePage GA, Moore EC (1958) Metabolic effects of 6-thioguanine. I. Studies on thioguanine-resistant and -sensitive Ehrlich ascites cells. Cancer Res 18:1232–1239PubMedGoogle Scholar
  244. Sawitsky A, Desposito F, Treat C (1970) Vincristine and cyclophosphamide therapy in generalized neuroblastoma: a collaborative study. Am J Dis Child 119:308–313Google Scholar
  245. Schabel FM, Trader MW, Laster WR, Wheeler GP, Witt MH (1978) Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 23:200–215PubMedGoogle Scholar
  246. Schanker LS, Jeffrey J J (1961) Active transport of foreign pyrimidines across the intestinal epithelium. Nature 190:727–728PubMedCrossRefGoogle Scholar
  247. Schrecker AW (1970) Metabolism of l-β-D-arabinofuranosylcytosine in leukemia LI210: nucleoside and nucleotide kinases in cell-free extracts. Cancer Res 30:632–641PubMedGoogle Scholar
  248. Scriver CR, Hechtman P (1970) Human genetics of membrane transport with emphasis on amino acids. Adv Hum Genet 1:211–274PubMedGoogle Scholar
  249. Scriver CR, Mohyuddin S (1968) Amino acid transport in kidney: heterogeneity of a-aminoisobutyric acid uptake. J Biol Chem 243:3207–3213PubMedGoogle Scholar
  250. Secret CJ, Hadfield JR, Beer CT (1972) Studies on the binding of 3H-vinblastine by rat blood platelets in vitro. Biochem Pharmacol 21:1609–1624PubMedCrossRefGoogle Scholar
  251. See YP, Carlsen SA, Till JE, Ling V (1974) Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta 373:242–252PubMedCrossRefGoogle Scholar
  252. Segal S, Schwartzman L, Blair A, Bertoli D (1967) Dibasic amino acid transport in rat kidney cortex slices. Biochim Biophys Acta 135:127–135PubMedCrossRefGoogle Scholar
  253. Shen WC, Rysser HJP (1979) Poly(L-lysine) and poly(D-lysine) conjugates of methotrexate: different inhibitory effect on drug-resistant cells. Mol Pharmacol 16:614–622PubMedGoogle Scholar
  254. Simard R, Cassingena R (1969) Actinomycin resistance in cultured hamster cells. Cancer Res 29:1590–1597PubMedGoogle Scholar
  255. Sirotnak FM (1980) Correlates of folate analog transport, pharmacokinetics and selective antitumor action. Pharmacol Ther 8:71–103CrossRefGoogle Scholar
  256. Sirotnak FM, Donsbaeh RC (1976) Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 36:1151–1158PubMedGoogle Scholar
  257. Sirotnak FM, Kurita S, Hutchison DJ (1968) On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Res 28:75–80PubMedGoogle Scholar
  258. Skinner SM, Lewis RW (1977) Anti-leukemic activity (LI210) of 6-mercaptopurine and its metallo complexes in mice. Res Commun Chem Pathol Pharmacol 16:183–186PubMedGoogle Scholar
  259. Skovsgaard T (1978a) Carrier-mediated transport of daunorubicin, adriamycin, and rubi-dazone in Ehrlich ascites tumor cells. Biochem Pharmacol 27:1221–1227PubMedCrossRefGoogle Scholar
  260. Skovsgaard T (1978b) Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38:1785–1791PubMedGoogle Scholar
  261. Skovsgaard T (1978c) Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38:4722–4727PubMedGoogle Scholar
  262. Skovsgaard T (1980) Circumvention of resistance to daunorubicin by N-acetyldaunorubi-cin in Ehrlich ascites tumor. Cancer Res 40:1077–1083PubMedGoogle Scholar
  263. Sladek NE (1971) Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res 31:901–908PubMedGoogle Scholar
  264. Slotnick I J, Sells BH (1964) Actinomycin resistance in Bacillus subtilis. Science 146:407–408PubMedCrossRefGoogle Scholar
  265. Sonneborn D, Rothstein H (1966) Tritiated actinomycin-D uptake by amphibian lens epithelial cells. J Cell Biol 31:163aGoogle Scholar
  266. States B, Segal S (1968) Developmental aspects of cystine transport in rat intestinal segments. Biochim Biophys Acta 163:154–162PubMedCrossRefGoogle Scholar
  267. Stevens J, Stevens YW, Rhodes J, Steiner G (1978) Differences in nuclear glucocorticoid binding between corticoid-sensitive and corticoid-resistant lymphocytes of mouse lymphoma P1798 and stabilization of nuclear hormone receptor complexes with carbobenzoxy-L-phenylalanine. J Natl Cancer Inst 61:1477–1485PubMedGoogle Scholar
  268. Stoll BA (1969) Hormone management of advanced breast cancer. Br Med J 2:293–297PubMedCrossRefGoogle Scholar
  269. Stutts P, Brockman RW (1963) A biochemical basis for resistance of LI210 mouse leukemia to 6-thioguanine. Biochem Pharmacol 12:97–104PubMedCrossRefGoogle Scholar
  270. Taylor EW (1965) The mechanism of colchicine inhibition of mitosis. J Cell Biol 25:145–160PubMedCrossRefGoogle Scholar
  271. Taylor JR (1959) Intravenous and oral trial of stilbestrol diphosphate in prostatic cancer. Can Med Assoc J 80:880–882PubMedGoogle Scholar
  272. Thomas AN, Gordan GS, Goldman L, Lowe R (1962) Antitumor efficacy of 2-a-methyl dihydrotestosterone propionate in advanced breast cancer. Cancer 15:176–178PubMedCrossRefGoogle Scholar
  273. Thomas EL, Christensen HN (1971) Nature of the cosubstrate action of Na+ and neutral amino acids in a transport system. J Biol Chem 246:1682–1688PubMedGoogle Scholar
  274. Thompson EB, Lippman ME (1974) The mechanism of action of glucocorticoids. Metabolism 23:159–202PubMedCrossRefGoogle Scholar
  275. Troshin AS (1966) Problems of cell permeability. Pergamon, Oxford, pp 16–20Google Scholar
  276. Trouet A, Deprez-De, Campeneere D, DeDuve C (1972) Chemotherapy through lyso-somes with a DNA-daunorubicin complex. Nature New Biol 239:110–112PubMedCrossRefGoogle Scholar
  277. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981a) Prevention of vinblastine-induced cytotoxicity by ruthenium red. Biochem Pharmacol 30:213–216PubMedCrossRefGoogle Scholar
  278. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981b) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972PubMedGoogle Scholar
  279. Uchida K, Kreis W (1969) Studies on drug resistance. I. Distribution of l-β-D-arabinofuranosylcytosine, cytidine and deoxycytidine in mice bearing ara-C-sensitive and -resistant P815 neoplasms. Biochem Pharmacol 18:1115–1128PubMedCrossRefGoogle Scholar
  280. Umezawa H (1975) Bleomycin. In: Corcoran JW, Hahn FE (eds) Antibiotics, vol 3. Springer, Berlin Heidelberg New York, pp 21–33Google Scholar
  281. van Putten LM, Lelieveld P (1971) Factors determining cell kill by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil, and nitrogen mustard. Eur J Cancer 7:11–16PubMedCrossRefGoogle Scholar
  282. Vistica DT (1979) Cytotoxicity as an indicator for transport mechanism: evidence that melphalan is transported by two leucine-preferring carrier systems in the LI210 murine leukemia cell. Biochim Biophys Acta 550:309–317PubMedCrossRefGoogle Scholar
  283. Vistica DT (1980) Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells. Blood 56:427–429PubMedGoogle Scholar
  284. Vistica DT, Schuette BP (1981) Carrier mechanism and specificity accounting for the increase in intracellular melphalan by the basic amino acids. Mol Pharmacol 19:92–96PubMedGoogle Scholar
  285. Vistica DT, Toal JN, Rabinovitz M (1976) Amino acid-conferred resistance to melphalan. I. Structure-activity relationship in cultured LI210 leukemia cells. Cancer Treat Rep 60:1363–1367PubMedGoogle Scholar
  286. Vistica DT, Toal JN, Rabinovitz M (1977) Amino acids affecting melphalan transport and cytotoxicity in cultured LI210 cells. Proc Am Assoc Cancer Res 18:26Google Scholar
  287. Vistica DT, Rabon A, Rabinovitz M (1978a) Interference with melphalan transport and therapy in the L1210 murine leukemia system, its significance and prevention. Proc Am Assoc Cancer Res 19:44Google Scholar
  288. Vistica DT, Rabon A, Rabinovitz M (1978 b) Enhancement of melphalan therapy with glu-taminase: asparaginase. Res Commun Chem Pathol Pharmacol 22:83–92Google Scholar
  289. Vistica DT, Toal JN, Rabinovitz M (1978 c) Amino acid-conferred protection against melphalan: characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured LI210 murine leukemia cells. Biochem Pharmacol 27:2865–2870Google Scholar
  290. Warren RD, Nichols AP, Bender RA (1977) The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells. Cancer Res 37:2993–2997PubMedGoogle Scholar
  291. Warren R, Nichols AP, Bender RA (1978) Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res 38:668–671PubMedGoogle Scholar
  292. Wheeler GP, Alexander JA (1964) Studies with mustards. V. In vivo fixation of C14 of labeled alkylating agents by bilaterally grown sensitive and resistant tumors. Cancer Res 24:1331–1337PubMedGoogle Scholar
  293. Winter CG, Christensen HN (1965) Contrasts in neutral amino acid transport by rabbit erythrocytes and reticulocytes. J Biol Chem 240:3594–3600PubMedGoogle Scholar
  294. Wira CR, Munck A (1974) Glucocorticoid-receptor complexes in rat thymus cells. J Biol Chem 249:5328–5336PubMedGoogle Scholar
  295. Wohlhueter RM, Mclvor RS, Plagemann PGW (1980) Facilitated transport of uracil and 5-fluorouracil and permeation of orotic acid in cultured mammalian cells. J Cell Physiol 104:309–319PubMedCrossRefGoogle Scholar
  296. Wolpert MK, Ruddon RW (1969) A study on the mechanism of resistance to nitrogen mustard (HN2) in Ehrlich ascites tumor cells; comparison of uptake of HN2-14C into sensitive and resistant cells. Cancer Res 29:873–879PubMedGoogle Scholar
  297. Wolpert MK, Damle SP, Brown JE, Sznycer E, Agrawal KC, Sartorelli AC (1971) The role of phosphohydrolases in the mechanism of resistance of neoplastic cells to 6-thiopurines. Cancer Res 31:1620–1626PubMedGoogle Scholar
  298. Yamada T, Iwanami Y, Baba T (1963) The transport of 14C-labeled nitrogen mustard N-oxide through cellular membrane treated with Tween 80 in vitro. Gann 54:171–176PubMedGoogle Scholar
  299. Yamagami H, Ishizawa M, Endo H (1974) Phenotypic and genetic characteristics of bleomycin sensitive mutants of Escherichia coli. Gann 65:61–67PubMedGoogle Scholar
  300. Yamamoto KR, Stampfer MR, Tomkins GM (1974) Receptors from glucocorticoid-sensitive lymphoma cells and two classes of insensitive clones: physical and DNA-binding properties. Proc Natl Acad Sci USA 71:3901–3905PubMedCrossRefGoogle Scholar
  301. York JL, LePage GA (1966) A proposed mechanism for the action of 9-β-D-arabinofuranosyladenine as an inhibitor of the growth of some ascites cells. Can J Biochem 44:19–26PubMedCrossRefGoogle Scholar
  302. Zager RF, Frisby SA, Oliverio VT (1973) The effects of antibiotics and cancer chemo therapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res 33:1670–1676PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • G. J. Goldenberg
  • A. Begleiter

There are no affiliations available

Personalised recommendations